Cite
HARVARD Citation
Paul, C. et al. (2018). Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials. Journal of the European Academy of Dermatology and Venereology. pp. 68-72. [Online].